Dr. Soumiya Swaminathan, chief scientist of the World Health Organization (WHO), explained on Monday that the hydroxychloroquine “arm” of the COVID-19 treatment Solidarity Trial was paused for enrollment due to the uncertainty surrounding the drug after a study published showed a potential higher mortality rate among COVID-19 patients taking the drug. She said the measures are temporary in order to examine published and unpublished studies on the drug.
- Alberta temporarily suspends hydroxychloroquine COVID-19 trial
- WHO pauses hydroxychloroquine coronavirus trial over safety concerns